8 results

More than 40 US states have alleged some generic drug firms are inflating drug prices. Photograph: Reuters

US states filed a lawsuit accusing Teva Pharmaceuticals of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – somet(...)

Novartis Institutes for BioMedical Research building in Cambridge, Massachusetts. Photograph: Scott Eisen/Bloomberg

Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson’s Remicade and Amgen’s Enbrel, citing a study it hopes(...)

Vas Narasimhan:  he will take over as Novartis CEO  in 2018

Novartis chief executive Joe Jimenez will step down on February 1st and hand over to drug development chief Vas Narasimhan to decide the fate of $50 b(...)

Photograph: Simon Dawson/Bloomberg

Lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe’s five top markets as much as €98 billion by(...)

The logo of Swiss pharmaceutical company Novartis is seen at the company’s plant in Hueninge, France

Swiss drugmaker Novartis has appointed a new head of its Alcon eye care division after the company fell short of fourth-quarter earnings expectations(...)

Robert J. Coury, vice chairman and chief executive officer of Mylan told investors he may sweeten the company’s cash-and-stock offer for  Perrigo, which has rejected Mylan’s most recent offer of $75 in cash and 2.3 Mylan shares for each Perrigo share. (Photograph: Mannie Garcia/Bloomberg News)

Mylan’s chairman told investors he may sweeten the company’s cash-and-stock offer for Irish headquartered Perrigo by adding terms to reduce the risk (...)

Swiss drug maker reported first-quarter profits beating estimates with operating income of $3.55 billion. Photograph: Reuters.

Novartis, the world’s biggest drugmaker by sales, reported first-quarter profits that beat analysts’ estimates as the company begins to benefit from a(...)

The high price of infant formula and drugs have become politically sensitive issues for Beijing

Beijing’s investigation of foreign companies for alleged price fixing has extended to the pharmaceuticals industry, with the National Development and (...)